High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis.


Journal Article

We describe 3 patients with left-sided staphylococcal endocarditis (1 with methicillin-susceptible Staphylococcus aureus [MSSA] prosthetic aortic valve endocarditis and 2 with methicillin-resistant S. aureus [MRSA] native-valve endocarditis) who were successfully treated with high-dose intravenous daptomycin (10 mg/kg/day) plus fosfomycin (2 g every 6 h) for 6 weeks. This combination was tested in vitro against 7 MSSA, 5 MRSA, and 2 intermediately glycopeptide-resistant S. aureus isolates and proved to be synergistic against 11 (79%) strains and bactericidal against 8 (57%) strains. This combination deserves further clinical study.

Full Text

Cited Authors

  • Miró, JM; Entenza, JM; Del Río, A; Velasco, M; Castañeda, X; Garcia de la Mària, C; Giddey, M; Armero, Y; Pericàs, JM; Cervera, C; Mestres, CA; Almela, M; Falces, C; Marco, F; Moreillon, P; Moreno, A; Hospital Clinic Experimental Endocarditis Study Group,

Published Date

  • August 2012

Published In

Volume / Issue

  • 56 / 8

Start / End Page

  • 4511 - 4515

PubMed ID

  • 22644033

Pubmed Central ID

  • 22644033

Electronic International Standard Serial Number (EISSN)

  • 1098-6596

International Standard Serial Number (ISSN)

  • 0066-4804

Digital Object Identifier (DOI)

  • 10.1128/aac.06449-11


  • eng